Burkholderia cepacia complex in cystic fibrosis: frequency of strain replacement during chronic infection.

Persons with cystic fibrosis (CF) are susceptible to chronic pulmonary infection due to certain Burkholderia species, but it is not clear whether this typically involves persistent infection with the same strain or sequential infection with distinct strains. We analyzed 1095 Burkholderia isolates recovered from serial sputum cultures from 379 patients with CF receiving care in 112 CF treatment centers in the United States. Genotyping was performed by random amplified polymorphic DNA typing or pulsed-field gel electrophoresis. Overall, a change in infecting strain was found in 24 (6.9%) of 347 patients infected with Burkholderia cepacia complex and in 3 (9%) of 32 patients infected with Burkholderia gladioli. Several patients were likely coinfected, at least transiently, with >1 B. cepacia complex strain. The potential for strain replacement during chronic infection may confound studies of the relationship between strain and clinical outcome and must be considered in designing effective infection-control practices.

[1]  Tom Coenye,et al.  Burkholderia cenocepacia sp. nov.--a new twist to an old story. , 2003, Research in microbiology.

[2]  T. Coenye,et al.  Comparative Assessment of Genotyping Methods for Epidemiologic Study of Burkholderia cepacia Genomovar III , 2002, Journal of Clinical Microbiology.

[3]  P. Vandamme,et al.  Burkholderia anthina sp. nov. and Burkholderia pyrrocinia, two additional Burkholderia cepacia complex bacteria, may confound results of new molecular diagnostic tools. , 2002, FEMS immunology and medical microbiology.

[4]  T. Coenye,et al.  Multilocus restriction typing: a novel tool for studying global epidemiology of Burkholderia cepacia complex infection in cystic fibrosis. , 2002, The Journal of infectious diseases.

[5]  M. Corey,et al.  Epidemiology of Burkholderia cepacia Complex in Patients with Cystic Fibrosis, Canada , 2002, Emerging infectious diseases.

[6]  P. Gilligan,et al.  Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex. Survival linked to genomovar type. , 2001, American journal of respiratory and critical care medicine.

[7]  P. Corris,et al.  Burkholderia cepacia complex genomovars and pulmonary transplantation outcomes in patients with cystic fibrosis , 2001, The Lancet.

[8]  J. Lipuma,et al.  Endemicity and inter-city spread of Burkholderia cepacia genomovar III in cystic fibrosis. , 2001, The Journal of pediatrics.

[9]  P. Vandamme,et al.  Infection with Burkholderia cepacia complex genomovars in patients with cystic fibrosis: virulent transmissible strains of genomovar III can replace Burkholderia multivorans. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  Tom Coenye,et al.  Taxonomy and Identification of the Burkholderia cepacia Complex , 2001, Journal of Clinical Microbiology.

[11]  J. Lipuma Burkholderia cepacia complex: a contraindication to lung transplantation in cystic fibrosis? , 2001, Transplant infectious disease : an official journal of the Transplantation Society.

[12]  M. Barchitta,et al.  Burkholderia cepacia Complex Infection in Italian Patients with Cystic Fibrosis: Prevalence, Epidemiology, and Genomovar Status , 2001, Journal of Clinical Microbiology.

[13]  J. Lipuma,et al.  Disproportionate distribution of Burkholderia cepacia complex species and transmissibility markers in cystic fibrosis. , 2001, American journal of respiratory and critical care medicine.

[14]  J. Emerson,et al.  Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. , 2001, The Journal of infectious diseases.

[15]  P. Vandamme,et al.  DNA-Based Diagnostic Approaches for Identification of Burkholderia cepacia Complex, Burkholderia vietnamiensis, Burkholderia multivorans,Burkholderia stabilis, and Burkholderia cepacia Genomovars I and III , 2000, Journal of Clinical Microbiology.

[16]  J. Burns,et al.  Aminoglycoside-resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment. , 2000, The Journal of infectious diseases.

[17]  P. Whitby,et al.  Species-Specific PCR as a Tool for the Identification of Burkholderia gladioli , 2000, Journal of Clinical Microbiology.

[18]  P. Vandamme,et al.  Development of rRNA-Based PCR Assays for Identification of Burkholderia cepacia Complex Isolates Recovered from Cystic Fibrosis Patients , 1999, Journal of Clinical Microbiology.

[19]  J. Lipuma,et al.  BURKHOLDERIA CEPACIA: Management Issues and New Insights , 1998 .

[20]  J. Emerson,et al.  Microbiology of sputum from patients at cystic fibrosis centers in the United States. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  C. Hart,et al.  Cross infection between cystic fibrosis patients colonised with Burkholderia cepacia , 1998, Thorax.

[22]  M. Kaufmann,et al.  Type characterisation and antibiotic susceptibility of Burkholderia (Pseudomonas) cepacia isolates from patients with cystic fibrosis in the United Kingdom and the Republic of Ireland. , 1996, Journal of medical microbiology.

[23]  P. Gilligan,et al.  Inapparent transmission of Pseudomonas (Burkholderia) cepacia among patients with cystic fibrosis , 1994, The Pediatric infectious disease journal.

[24]  M. Dodd,et al.  Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis , 1993, The Lancet.

[25]  T. Stull,et al.  Marked phenotypic variability in Pseudomonas cepacia isolated from a patient with cystic fibrosis , 1993, Journal of clinical microbiology.

[26]  J. Lipuma,et al.  Ribotype stability of serial pulmonary isolates of Pseudomonas cepacia. , 1991, The Journal of infectious diseases.

[27]  T. Edlind,et al.  A broad-spectrum probe for molecular epidemiology of bacteria: ribosomal RNA. , 1988, The Journal of infectious diseases.

[28]  M. Corey,et al.  Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. , 1984, The Journal of pediatrics.